- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04772157
Safe Emergency Department dIscharGE Rate (SEIGE) (SEIGE)
Evaluation of the Siemens POC HS cTn-I Test System
The Siemens POC High Sensitivity Troponin-I Test System is an in vitro diagnostic test for the quantitative measurement of cardiac troponin I (cTn-I) in fresh human capillary (fingerstick) whole blood, and lithium-heparinized venous whole blood or plasma, to be used by healthcare professionals at the point of care (POC) as well as in the clinical laboratory.
The Siemens POC High Sensitivity Troponin-I Test System is to be used as an aid in the diagnosis of myocardial infarction (MI).
Study Overview
Status
Intervention / Treatment
Detailed Description
Study purpose/objective:
- Evaluate the clinical performance of the Siemens POC HS cTn-I test system for the diagnosis and rule out of AMI in patients presenting to the emergency department in whom serial cTnI measurements are obtained on clinical indication.
- Correlate the blood and plasma outcomes on the Siemens POC HS cTn-I test system as function of the corresponding hematocrit (Hct) values.
Hypothesis: The Siemens POC HS cTn-I Test System will offer an excellent diagnostic performance for acute myocardial injury and acute myocardial infarction, as well as expedite the risk stratification of patients for early discharge from the emergency department.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55404
- Hennepin Healthcare Research Institute / Hennepin County Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Presents to the ED, or ambulatory care center equivalent, with signs or symptoms suspicious of a possible ACS event.
- Baseline cTn-I measurement and one additional cTn-I measurement at two hours after the first measurement.
- At least one 12-lead electrocardiogram
Exclusion Criteria
- Less than 21 years old
- Pregnancy
- Trauma
- Declines to participate or has indicated that their blood/ medical information cannot be used for investigational purposes
- Did not present through the ED
- Transferred from an outside hospital or clinic.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Cohort
Study population: Prospective, observational cohort study of consecutives patients (goal, 1000 patients over 4 months) presenting to the emergency department, in whom serial cTnI measurements are ordered on clinical indication at Hennepin Healthcare / Hennepin County Medical Center (Minneapolis, MN, USA) to rule-in and rule-out acute myocardial infarction.
|
Lithium heparin whole blood and plasma samples will be measured with Siemens POC High Sensitivity Troponin-I Test System.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Examine the incidence of undetectable(<LoD), measurable (LoD - 99th percentile), and increased (>99th percentile) cTn concentrations for the Siemens POC HS cTn-I Test System
Time Frame: Day 1
|
Examine the incidence of undetectable(<LoD), measurable (LoD - 99th percentile), and increased (>99th percentile) cTn concentrations for the Siemens POC HS cTn-I Test System in comparison to a high sensitivity cTnI assay (Abbott & Siemens Healthineers) to determine the potential impact on positivity rate, defined by sex-specific 99th percentiles.
|
Day 1
|
Examine Concordance
Time Frame: Day 1
|
Examine concordance (dis) between hs-cTnI in comparison to a high sensitivity (Abbott & Siemens Healthineers) cTnI assay
|
Day 1
|
Examine the diagnostic performance for acute myocardial injury and acute myocardial infarction
Time Frame: Day 1
|
Examine the diagnostic performance for a) acute myocardial injury and b) acute myocardial infarction based on various diagnostic strategies using hs-cTnI measurement(s), as follows:
|
Day 1
|
Describe the incidence, clinical characteristics and outcomes of patients with and without hs-cTnI increases above the sex-specific 99th percentile URLs
Time Frame: Day 1
|
Describe the incidence, clinical characteristics and outcomes of patients with and without hs-cTnI increases above the sex-specific 99th percentile URLs, including patients categorized with acute myocardial injury and acute myocardial infarction, including type 1 and 2 myocardial infarction following the 4th Universal Definition of Myocardial Infarction.
|
Day 1
|
Impact on the incidence of myocardial injury and myocardial infarction diagnoses.
Time Frame: Day 1
|
Examine the potential impact on the incidence of myocardial injury and myocardial infarction diagnoses using hs-cTnI upon clinical practice implementation with a comparison to the hospital's final ICD-10 code diagnosis of type 1 and type 2 MIs.
|
Day 1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adjudicated index acute myocardial infarction according to 4th UDMI
Time Frame: on admission
|
acute myocardial infarction, including sub-types following the Fourth Universal Definition of Myocardial Infarction
|
on admission
|
Safety Outcome - MACE
Time Frame: 30 days
|
Major Adverse Cardiovascular Event - cardiac death, myocardial infarction, revascularization, congestive heart failure
|
30 days
|
All-cause mortality
Time Frame: up to 30 days
|
any death
|
up to 30 days
|
Cardiac mortality
Time Frame: up to 30 days
|
death due to cardiac reasons
|
up to 30 days
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Fred S Apple, PhD, Hennepin Healthcare Research Institute
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SEIGE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Coronary Syndrome
-
Yonsei UniversityRecruitingCoronary Artery Disease, Acute Coronary SyndromeKorea, Republic of
-
Meditrix CorpNational University of Ireland, Galway, Ireland; Boston Scientific Japan K.K.; Fujita Health UniversityRecruitingChronic Coronary Syndrome | Non ST Segment Elevation Acute Coronary SyndromeJapan, Ireland
-
OrbusNeichDuke Clinical Research Institute; OrbusNeich Medical K.K.CompletedCoronary Arteriosclerosis | Non ST Segment Elevation Acute Coronary SyndromeUnited States, Japan
-
Medical University of WarsawRecruitingAcute Coronary Syndrome | Chronic Coronary Syndrome | Non ST Segment Elevation Acute Coronary SyndromePoland
-
Niguarda HospitalCompletedAcute Coronary Syndrome With ST Elevation on Electrocardiogram | Acute Coronary Syndrome Without ST Elevation on Electrocardiogram | Noncritical Coronary Artery Disease Coronary Stenosis Less Than 50 Per Cent | Aortic AneurysmsItaly
-
Sohag UniversityRecruitingLeft Main Coronary Artery Disease With Acute Coronary SyndromeEgypt
-
Eli Lilly and CompanyDaiichi Sankyo, Inc.CompletedCoronary Arteriosclerosis | Acute Coronary SyndromesUnited States
-
University of PatrasCompletedCoronary Artery Disease (CAD) | Acute Coronary Syndrome (ACS)Greece
-
Deutsches Herzzentrum MuenchenDeutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)CompletedAcute Coronary Syndrome (ACS)Germany, Italy
-
Northwestern UniversityTerminatedACS - Acute Coronary SyndromeUnited States
Clinical Trials on Cardiac Troponin Testing
-
Hennepin Healthcare Research InstituteAbbott Diagnostics Division; Hennepin County Medical Center, MinneapolisActive, not recruitingAcute Coronary Syndrome | Acute Myocardial InfarctionUnited States
-
Hospital de Clinicas de Porto AlegreUnknownPostoperative Complications | Patient Care TeamBrazil
-
Hennepin Healthcare Research InstituteSiemens HealthineersActive, not recruitingAcute Coronary Syndrome | Acute Myocardial InfarctionUnited States
-
Hennepin Healthcare Research InstituteMindray Bio-Medical Electronics Co., Ltd.Active, not recruitingAcute Coronary Syndrome | Acute Myocardial InfarctionUnited States
-
Columbia UniversityRoche Pharma AGCompleted
-
Assiut UniversityNot yet recruitingPulmonary Embolism
-
Poitiers University HospitalCompleted
-
Universitair Ziekenhuis BrusselUnknownMortality | Surgery--Complications | ElderlyBelgium
-
Oncology Institute of Southern SwitzerlandCardiocentro Ticino; North Estonia Medical Centre; Fondazione IRCCS Policlinico...RecruitingCardiotoxicitySwitzerland
-
National Institute of Mental Health and Neuro Sciences...Completed